23June

Novo Nordisk reports up to 13.8% weight loss in people with obesity receiving se ... Read more

23June

Novo Nordisk A/S: CHMP adopts positive opinion for EU label update of Victoza® b ... Read more

22June

Novo Nordisk A/S: CHMP endorses EU label update of Saxenda® based on the LEADER ... Read more

20June

Novo Nordisk receives positive 17-2 vote from FDA Advisory Committee that Victoz ... Read more

26June

Novo Nordisk A/S - Share repurchase programme ... Read more

23June

Novo Nordisk reports up to 13.8% weight loss in people with obesity receiving se ... Read more

23June

Novo Nordisk A/S: CHMP adopts positive opinion for EU label update of Victoza® b ... Read more

22June

Novo Nordisk A/S: CHMP endorses EU label update of Saxenda® based on the LEADER ... Read more

09July

ISTH 2017, Berlin

01July

Silent period,

09August

Financial statement for the first six months of 2017,

29August

Commerzbank Sector Conference, Frankfurt

 

 

 

Investors

 
Share information


Take an advanced view of the Novo Nordisk share

 
Q1 2017 financial results 


Q1 2017 conference call and roadshow presentation

 
ADA 2017


Investor presentation ADA 2017 webcast and presentation



Novo Nordisk at a glance


Private shareholders


See relevant content for private investors



IR material


Download relevant Investor Relations material



Contacts



Subscriptions


Sign up to receive company announcements.


LEADER AdCom